Top Page
CSL
(Sydney:CSL)
CSL (CSL) vs. iShares MSCI Australia ETF (EWA)
CSL Business Overview & Revenue Model
CSL Earnings Call Summary
CSL Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.98B | 15.43B | 14.69B | 13.17B | 10.49B | 10.33B |
| Gross Profit | 7.36B | 7.95B | 7.56B | 6.71B | 5.66B | 5.80B |
| EBITDA | 4.98B | 5.13B | 4.73B | 3.90B | 3.46B | 2.72B |
| Net Income | 3.12B | 3.00B | 2.64B | 2.19B | 2.25B | 2.39B |
Balance Sheet | ||||||
| Total Assets | 38.45B | 39.40B | 38.02B | 54.43B | 41.22B | 18.16B |
| Cash, Cash Equivalents and Short-Term Investments | 1.52B | 2.16B | 1.66B | 2.33B | 15.18B | 1.81B |
| Total Debt | 11.96B | 11.50B | 12.18B | 18.37B | 14.04B | 5.81B |
| Total Liabilities | 17.90B | 18.00B | 18.62B | 27.65B | 20.02B | 9.74B |
| Stockholders Equity | 18.56B | 19.34B | 17.33B | 23.72B | 21.20B | 8.38B |
Cash Flow | ||||||
| Free Cash Flow | 2.03B | 2.54B | 1.51B | 1.35B | 1.90B | 1.97B |
| Operating Cash Flow | 2.97B | 3.56B | 2.81B | 3.87B | 3.62B | 3.65B |
| Investing Cash Flow | -924.09M | -850.00M | -1.26B | -17.61B | -2.26B | -1.68B |
| Financing Cash Flow | -1.43B | -2.24B | -1.28B | 677.92M | 10.58B | -1.41B |
CSL Technical Analysis
CSL Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $2.71B | 18.33 | 54.79% | ― | 12.35% | 26.73% | |
| ― | $86.29B | 18.57 | 16.36% | 2.67% | 6.07% | 13.75% | |
| ― | $572.79M | 15.66 | 15.90% | 0.44% | 7.76% | 1.55% | |
| ― | $5.56B | 329.92 | 3.21% | ― | 60.23% | -66.98% | |
| ― | $3.22B | ― | -18.95% | ― | 198.58% | 3.97% | |
| ― | $419.50M | ― | -35.86% | ― | ― | -19.21% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CSL Corporate Events
CSL Limited has announced the cessation of Megan Clark as a director, effective October 28, 2025. This change in the board composition is accompanied by details of her interests in the company’s securities, which include 3,883 ordinary fully paid shares held directly and additional shares and rights held indirectly through Solium Nominees (Australia) Pty Ltd. This update is part of CSL’s compliance with regulatory requirements and may influence stakeholders’ perspectives on the company’s governance and strategic direction.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$275.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited’s 2025 Annual General Meeting, held in Melbourne, revealed key shareholder voting outcomes on several resolutions. Notably, the ‘second strike’ against the Remuneration Report was recorded, triggering a conditional Spill Resolution, which was ultimately not carried. The meeting also saw the election of directors and approval of performance share units, reflecting the company’s ongoing governance and strategic initiatives.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited held its 2025 Annual General Meeting in Melbourne, where key updates were provided regarding financial projections for 2026-2028 and a proposal to demerge CSL Seqirus. The meeting underscored the company’s strategic direction amidst current market challenges, emphasizing its commitment to sustainable and profitable growth. The AGM also highlighted changes in board membership, with some directors retiring and others standing for election, reflecting a robust governance structure.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing share buyback program, with UBS Securities Australia Limited replacing JP Morgan as the broker. This change in broker details signifies a strategic adjustment in the execution of CSL’s buyback plan, potentially impacting its market operations and shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$300.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced the cessation of 9,078 securities due to the lapse of conditional rights as the conditions were not met or became incapable of being satisfied. This announcement may impact CSL’s capital structure and could have implications for stakeholders regarding the company’s operational strategies and market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$300.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of October 6, 2025, the company has repurchased a total of 1,729,549 ordinary fully paid securities, with 56,837 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure effectively, potentially enhancing shareholder value and optimizing the company’s financial performance.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$300.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of October 3, 2025, the company has repurchased a total of 1,584,356 ordinary fully paid securities, with an additional 88,356 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and return value to shareholders, potentially impacting its stock market performance and investor relations.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced the appointment of Cameron Bruce Price as a new director, effective from October 1, 2025. This appointment is part of the company’s ongoing efforts to strengthen its leadership team, potentially impacting its strategic direction and stakeholder relations. Mr. Price holds no direct shares but has an indirect interest through his wife, who owns 3,296 ordinary shares.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced the appointment of Mr. Ken Lim as the new Chief Financial Officer, effective October 7, 2025, succeeding Ms. Joy Linton, who will retire after a transition period. Mr. Lim, previously the Chief Strategy Officer, brings over a decade of experience at CSL, and his appointment reflects the company’s strong executive talent pool. This leadership change is expected to maintain CSL’s strategic direction and continue delivering value to its stakeholders.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of September 29, 2025, the company has bought back a total of 1,476,163 securities, with an additional 108,193 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategic financial management, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$285.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing share buy-back program. As of September 26, 2025, the company has repurchased a total of 1,476,163 ordinary fully paid securities, with 74,423 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting positively on its market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$285.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of September 24, 2025, the company has bought back a total of 1,311,784 securities, including 62,957 on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and return value to shareholders, potentially impacting its market positioning by reducing the number of outstanding shares.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$285.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 19, 2025, the company has repurchased a total of 906,265 ordinary fully paid securities, with an additional 130,000 securities bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting confidence in its financial health and future growth prospects.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 773,583 securities bought back before the previous day and an additional 132,682 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders, potentially enhancing the company’s stock performance and market perception.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced the details for its 2025 Annual General Meeting, scheduled to take place on October 28, 2025, at the RACV Club in Melbourne. This meeting is a significant event for shareholders, providing an opportunity to discuss the company’s performance and future strategies, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has partnered with Dutch biotech firm VarmX to develop VMX-C001, a first-in-class treatment aimed at restoring blood coagulation in patients on FXa inhibitors who experience severe bleeding or require urgent surgery. This collaboration aligns with CSL’s strategy to expand its clinical and commercial pipeline through external partnerships. The U.S. FDA has granted Fast Track Designation to VMX-C001, highlighting its potential to meet a critical unmet medical need. CSL will fund the global Phase 3 trial and has secured an exclusive option to acquire VarmX, with commercial launch anticipated in 2029.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update on its ongoing on-market buy-back program. As of September 15, 2025, the company has repurchased a total of 773,583 ordinary fully paid securities, with 47,865 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has updated its previous dividend announcement to include details on currency rates and local currency conversions. This update pertains to the dividend distribution for the six-month period ending June 30, 2025, with a record date of September 10, 2025. The announcement reflects the company’s ongoing commitment to transparency and provides stakeholders with crucial financial information.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 12, 2025, the company has repurchased a total of 725,718 ordinary fully paid securities, with 135,502 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 11, 2025, the company has repurchased a total of 590,216 ordinary fully paid securities, with 64,826 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and return value to shareholders.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced the issuance of 1,592,335 unquoted securities under an employee incentive scheme. These securities are subject to transfer restrictions and will not be quoted on the ASX until the restrictions are lifted. This move is part of CSL’s strategy to incentivize and retain talent, which is crucial for maintaining its competitive edge in the biotechnology sector.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced the issuance of 150,485 ordinary fully paid securities under an employee incentive scheme, which are set to be quoted on the Australian Securities Exchange. This move is part of CSL’s efforts to incentivize its workforce and align employee interests with company performance, potentially impacting its market positioning and stakeholder engagement positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. As of September 10, 2025, the company has repurchased a total of 396,615 ordinary fully paid securities, with 128,775 bought back on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of September 9, 2025, the company reported buying back a total of 292,931 securities before the previous day and an additional 103,684 securities on the previous day. This buy-back initiative is part of CSL’s strategy to manage its capital structure efficiently, potentially enhancing shareholder value by reducing the number of outstanding shares.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its ongoing on-market buy-back program. The company reported that it bought back 143,219 ordinary fully paid securities on the previous day, adding to a total of 149,712 securities bought back before that day. This buy-back initiative is part of CSL’s strategy to manage its capital structure and return value to shareholders, which may impact its stock liquidity and share price.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced a change in the director’s interest, specifically involving Dr. Paul McKenzie’s indirect holdings. The change included the acquisition of 8,101 ordinary shares and the disposal of 3,699 ordinary shares, along with the exercise and lapse of performance share units under the company’s Performance Rights Plan. This adjustment reflects the company’s ongoing management of executive compensation and performance incentives, which may impact shareholder value and align leadership interests with company performance.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced the cessation of 110,017 securities due to the lapse of conditional rights as the conditions were not met by September 1, 2025. This announcement may impact the company’s capital structure and could have implications for stakeholders, reflecting the company’s ongoing adjustments in its securities management.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update on its ongoing share buy-back program, with 149,712 ordinary shares purchased on the previous day through JP Morgan Securities Australia Limited. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting the company’s robust financial health and commitment to returning capital to its investors.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced the quotation of 788,786 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 1, 2025. This move reflects the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its financial standing and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an update regarding its on-market share buyback program, appointing J.P. Morgan Securities Australia Limited as the broker for the transaction. This strategic move is part of CSL’s ongoing efforts to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its position in the market.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced a change in the director’s interest, specifically regarding Ms. Alison Watkins AM. The change involves the acquisition of 427 rights under the CSL Limited Non-Executive Director Rights Plan, with a consideration of $93,670.26. This move reflects the company’s ongoing commitment to aligning director interests with shareholder value, potentially impacting CSL’s governance and stakeholder confidence positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced the issuance of 3,550 unquoted securities under an employee incentive scheme. These securities are subject to transfer restrictions and are not listed on the ASX until the restrictions are lifted, which reflects CSL’s strategy to incentivize its workforce while maintaining a controlled equity structure.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced a change in the director’s interest, specifically involving Ms. Alison Watkins AM, who has acquired 154 Ordinary Shares through the exercise of rights under the CSL Limited Non-Executive Director Rights Plan. This transaction reflects the company’s ongoing commitment to aligning director interests with shareholder value, as directors contribute a portion of their board fees to acquire equity, potentially impacting CSL’s governance and stakeholder confidence positively.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced an on-market buy-back of its ordinary fully paid shares. This strategic move is likely aimed at optimizing the company’s capital structure and potentially enhancing shareholder value. The buy-back could also signal the company’s confidence in its current market position and future prospects.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$293.83 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited is a global biopharmaceutical company specializing in plasma-derived therapies, vaccines, and biotechnology, with a focus on addressing unmet medical needs across more than 100 countries. In its 2024/25 annual report, CSL Limited reported a strong financial performance with an annual revenue of US$15.6 billion and a dividend of US$2.92 per share. The company highlighted significant growth in its immunoglobulin portfolio and the successful launch of new products like Andembry, a treatment for hereditary angioedema. CSL also announced strategic initiatives, including a proposal to demerge CSL Seqirus to enhance focus and growth. Looking forward, CSL aims to continue its trajectory of sustainable growth by focusing on operational excellence, strategic partnerships, and innovation in its therapeutic areas, while maintaining a strong commitment to sustainability and patient impact.
CSL Limited has released its corporate governance statement for the financial year ending June 30, 2025. The statement, which complies with the ASX Corporate Governance Council’s principles and recommendations, outlines the company’s adherence to governance practices, including board roles, director appointments, and accountability of the company secretary. This disclosure is part of CSL’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and the company’s industry standing.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced its full-year financial results for the year ending June 30, 2025. The results presentation, led by the CEO and CFO, will be webcast live, providing stakeholders with insights into the company’s financial performance and strategic direction. This announcement is significant as it reflects CSL’s ongoing commitment to transparency and its strategic positioning within the biotechnology industry.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited has announced a new dividend distribution of USD 1.62 per share for its ordinary fully paid securities. The dividend relates to the six-month period ending June 30, 2025, with an ex-date of September 9, 2025, a record date of September 10, 2025, and a payment date of October 3, 2025. This announcement underscores CSL’s commitment to providing shareholder value and reflects its stable financial performance, potentially enhancing its attractiveness to investors.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced a significant transformation initiative aimed at enhancing its operational efficiency and shareholder value. The company reported a 17% increase in net profit after tax for the fiscal year 2025, driven by strong performances in its CSL Behring and CSL Vifor segments. The strategic plan includes a demerger of CSL Seqirus, a share buyback program, and a focus on cost savings and reinvestment in growth opportunities. These changes are expected to streamline operations, reduce costs, and foster sustainable growth, although they will result in a 15% reduction in the workforce and restructuring costs of up to $770 million.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
CSL Limited announced its financial results for the year ending June 30, 2025, reporting a 5% increase in total revenue to US$15.558 billion and a 14% rise in net profit after tax (NPAT) to US$3.002 billion. The company also declared an unfranked final dividend of US$1.62 per share. These results reflect CSL’s strong performance and growth in the biotechnology sector, positioning it well for future advancements and stakeholder confidence.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.